A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03316898 |
|
Recruitment Status :
Withdrawn
(Business decision to stop the study.)
First Posted : October 20, 2017
Last Update Posted : November 2, 2018
|
Sponsor:
Allergan
Information provided by (Responsible Party):
Allergan
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's Disease on a stable dose of 10 mg donepezil with or without memantine standard of care.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer's Disease | Drug: AGN-242071 Drug: Placebo Drug: Donepezil Drug: Memantine | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease |
| Estimated Study Start Date : | September 30, 2018 |
| Estimated Primary Completion Date : | November 4, 2018 |
| Estimated Study Completion Date : | November 4, 2018 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Alzheimer disease
MedlinePlus related topics:
Alzheimer's Disease
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
|
Drug: Placebo
Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care. Drug: Donepezil Donepezil 10 mg as prescribed by the physician as per standard of care. Drug: Memantine Memantine as prescribed by the physician as per standard of care. |
|
Experimental: AGN-242071 5 mg
One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
|
Drug: AGN-242071
AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care. Drug: Placebo Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care. Drug: Donepezil Donepezil 10 mg as prescribed by the physician as per standard of care. Drug: Memantine Memantine as prescribed by the physician as per standard of care. |
|
Experimental: AGN-242071 15 mg
AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
|
Drug: AGN-242071
AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care. Drug: Placebo Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care. Drug: Donepezil Donepezil 10 mg as prescribed by the physician as per standard of care. Drug: Memantine Memantine as prescribed by the physician as per standard of care. |
|
Experimental: AGN-242071 25 mg
AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
|
Drug: AGN-242071
AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care. Drug: Placebo Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care. Drug: Donepezil Donepezil 10 mg as prescribed by the physician as per standard of care. Drug: Memantine Memantine as prescribed by the physician as per standard of care. |
Primary Outcome Measures :
- Change from Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR) for Whole Brain, Hippocampal and Dorsolateral Prefrontal Cortices [ Time Frame: Baseline (Day -3 to Day -1) to Day 28 ]The effects of AGN-242071 on brain metabolic activity or glucose metabolism will be determined using the FDG-PET scan by reporting results as SUVR.
- Percentage of Participants with Treatment-Emergent Adverse Events (TEAE) [ Time Frame: Day 1 to Day 35 ]An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE that occurs during the treatment period will be considered a TEAE if it was not present before the first dose or if it was present but increased in severity during the treatment period.
- Percentage of Participants with Changes from Baseline in Clinically Significant Clinical Laboratory Values [ Time Frame: Baseline (Day -3 to Day -1) to Day 35 ]Clinical laboratory safety tests include Chemistry, Hematology and Urinalysis.
- Percentage of Participants with Changes from Baseline in Clinically Significant Vital Signs [ Time Frame: Baseline (Day -3 to Day -1) to Day 35 ]Vital signs include systolic and diastolic blood pressure, pulse rate, weight, respiration rate, and temperature.
- Percentage of Participants with Changes from Baseline in Clinically Significant Electrocardiogram (ECG) Findings [ Time Frame: Baseline (Day -3 to Day -1) to Day 35 ]A standard 12-lead ECG will be performed.
- Percentage of Participants who have Suicidal Ideation or Behaviours as determined by Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Baseline (Day 1) to Day 35 ]The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior since the last visit.
- Clearance of AGN-242071 [ Time Frame: Day 1 to Day 28 ]Clearance will be determined utilizing a population pharmacokinetic (PK) approach implemented in non-linear mixed effects modeling (NONMEM®) software.
- Volume of Distribution of AGN-242071 [ Time Frame: Day 1 to Day 28 ]Volume of Distribution will be determined utilizing a population PK approach implemented in NONMEM® software.
- Cmax: Maximum Plasma concentration for AGN-242071 [ Time Frame: Day 28 ]
- AUC: Area Under the Curve for AGN-242071 [ Time Frame: Day 28 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnostic evidence of probable Alzheimer's Disease (AD) per the 2011 National Institutes of Aging-Alzheimer's Association (NIA-AA) criteria
- Participants receiving donepezil at a stable dose of 10 mg daily with or without stable dose memantine for at least 6 weeks prior to the screening visit.
Exclusion Criteria:
- Participants with illness apart from AD that could contribute to cognitive dysfunction
- History of clinically significant suicidal ideation within the past 6 months
- Thyroid disease unless the participant is euthyroid and stable on treatment for at least 3 months prior to screening
- Participants with a personal or family history of congenital long QT syndrome or sudden death
- Clinically significant cardiovascular disease in the past 6 months prior to screening
- Participants with signs and symptoms of peripheral vascular disease (PVD)
- A transient ischemic attack or other acute ischemic event affecting the brain, spinal cord, or peripheral circulation in the past 6 months prior to screening
- Any history of cerebrovascular accident or stroke
- Any history of a seizure disorder other than a single febrile seizure
- Pulmonary disease or evidence of clinically significant moderate or severe pulmonary symptoms
- History of cancer within the last 5 years
- Evidence or history of diabetes mellitus Type 1
- Any significant sensory (eg, moderate to severely impaired hearing or severely impaired vision) or hand movement difficulties that would prevent participants from completing the behavioral assessments of the study
- Treatment with cholinesterase inhibitors other than donepezil or other cholinomimetics within 12 weeks of the baseline visit
- Treatment with memantine not in combination with donepezil within 12 weeks of the baseline Visit
- Participants who have been on anticholinergic and/or antimuscarinic treatment including overactive bladder treatments, antihistamines, antipsychotics, and tricyclic antidepressants, within 12 weeks prior to the baseline visit
- Participants who have been on drugs that are strong inhibitors of CYP2D6 or CYP2C9 (eg, quinidine, paroxetine, fluoxetine, terbinafine, bupropion), or that are moderate or strong inhibitors of CYP3A4 (eg, erythromycin, ketoconazole, rifampicin, fluconazole, carbamazepine) within 21 days prior to the baseline visit
- Participants who are taking any moderate or strong inducers of CYP3A4 (eg, carbamazepine, phenytoin, rifampin, modafinil, and herbal preparations containing St. John's wort) or strong inducers of CYP2C9 within 21 days prior to the baseline visit
- Participants who have been on other drugs that could affect cognition (eg, benzodiazepines or gamma-aminobutyric acid A (GABAA) receptor agonists used as anxiolytics, sedative-hypnotics) or over-the-counter (OTC) sleeping aids within 12 weeks prior to the baseline visit
- Participants who have been on hormone replacement therapy, thyroid supplement, vitamin E, or vitamin B12 unless at a stable dose for 4 weeks before the baseline visit
- Use of an active Alzheimer's disease vaccine within 2 years prior to screening or monoclonal antibody for treatment of AD within 1 year prior to screening
- Positive test results for anti-human immunodeficiency virus (anti-HIV) type 1 and 2, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (anti-HCV) at screening
- Positive test results for urine drug screen for methadone, cocaine, tetrahydrocannabinol, benzodiazepines, tricyclic antidepressants, barbiturates, phencyclidine, amphetamines, methamphetamine, and opiates at screening or baseline visit
- Participants with a body weight of less than 40 kg
- Consumption of food or drinks containing grapefruit juice, cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus fruits or Seville orange or of alcohol within 72 hours before administration of study treatment.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03316898
Locations
| United States, California | |
| ATP Clinical Research | |
| Costa Mesa, California, United States, 94105 | |
| Irvine Center for Clinical Research | |
| Irvine, California, United States, 92614 | |
| Synergy Research Centers | |
| Lemon Grove, California, United States, 91945 | |
| Collaborative Neuroscience | |
| Long Beach, California, United States, 90806 | |
| Alliance Research | |
| Long Beach, California, United States, 90807 | |
| Syrentis Clinical Research | |
| Santa Ana, California, United States, 92705 | |
Sponsors and Collaborators
Allergan
Investigators
| Study Director: | Mitalee Tamhane, PhD | Allergan |
| Responsible Party: | Allergan |
| ClinicalTrials.gov Identifier: | NCT03316898 |
| Other Study ID Numbers: |
3142-101-001 |
| First Posted: | October 20, 2017 Key Record Dates |
| Last Update Posted: | November 2, 2018 |
| Last Verified: | October 2018 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Memantine Donepezil Cholinesterase Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Nootropic Agents Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents |